
Data from the MUST-ARDS trial were presented. ARDS remains to be a significant clinical condition with severe short-term and long-term consequences. Adult progenitor cell-expanding therapy may improve 28-day mortality, lessened ventilator and ICU burden, and demonstrated overall safety in patients with ARDS.
The effects of nintedanib on lung function decline were investigated in systemic sclerosis-associated ILD. The SENSCIS trial, a randomised control trial studying the efficacy of nintedanib vs placebo on respiratory function among patients with interstitial lung disease mediated by systemic sclerosis (SSc-ILD), found a slower forced vital capacity decline in patients treated with nintedanib.
New post-hoc analyses from the large-scale GRIPHON trial assessing selexipag, an oral selective prostacyclin I2 receptor agonist, in patients with pulmonary arterial hypertension demonstrated that early, aggressive treatment after diagnosis is associated with the greatest benefits, irrespective of background therapy.
Dupilumab, which inhibits both the IL-4 and IL-13 pathways, improves outcomes in patients with severe chronic rhinosinusitis with nasal polyps and comorbid asthma, as shown by a pooled analysis of the SINUS-24 and SINUS-52 trials.
E-cigarette use disrupts normal immune response to viral infections, particularly in women. A
preliminary study explored differences in immune response between non-smokers and people who use cigarettes or e-cigarettes by inoculating 47 participants with live attenuated influenza virus. They found that at baseline, e-cigarette use disrupted normal immune response to viral infections, especially for women and girls.
The short- and long-term data on the effects and safety of biological agents in the treatment of severe asthma are accumulating and may guide to further personalise pharmacological treatment. Modulators of IL-5 and IL-4/IL-13 activity show important effects on exacerbation rates, hospitalisations, and dose of oral corticosteroids. Insights into relevant patient phenotypes are increasing and contribute to personalised treatment in patients with severe asthma.
If you have not been able to experience these aspects of the ATS yourself, this report will outline the most significant advancements discussed at the conference, and practical advices disseminated there. So, we hope that you will enjoy reading this Conference Report!
Kind regards,
Prof. Richard Dekhuijzen
Biography
Prof. P.N. Richard Dekhuijzen is Professor of Pulmonology at the Radboud University Medical Center in Nijmegen, the Netherlands. His specific area of clinical and research interest includes asthma, COPD, and inhalation technology. He studied medicine at VU Amsterdam and completed his training in pulmonology at the Onze Lieve Vrouwe Gasthuis in Amsterdam and in the Academic Hospital Nijmegen. In 1989, he finished his PhD thesis on training of the respiratory muscles in COPD, followed by a PhD thesis on steroid induced myopathy of the diaphragm in 1994 at the Catholic University Leuven (Belgium). He is author/co-author of over 330 peer-reviewed papers and many textbook chapters on respiratory medicine. From 2008-2010, he was Head of the Cardiology Department at Radboudumc. Until 2016, he chaired the Department of Pulmonary Diseases, the Heart-Lung Centre Nijmegen, and the Medical Staff at Radboudumc. He is the scientific chair of the Aerosol Drug Management Improvement Team (ADMIT) and chair of the Dutch Inhalation Technology Working Group. Currently, he is chair of the Medical Ethical Committee of the
Radboudumc.
Conflict of Interest Statement:
In the last 3 years, Richard Dekhuijzen and/or his department received research grants, unrestricted educational grants, and/or fees for lectures and advisory board meetings from AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK, Mundipharma, Novartis, Sandoz, Teva, and Zambon.
Posted on
Previous Article
« Bacterial pneumonia predicts ongoing lung problems in infants hospitalised for acute respiratory failure Next Article
CORTICO-COP trial: eosinophil-guided therapy reduces systemic corticosteroid exposure »
« Bacterial pneumonia predicts ongoing lung problems in infants hospitalised for acute respiratory failure Next Article
CORTICO-COP trial: eosinophil-guided therapy reduces systemic corticosteroid exposure »
Table of Contents: ATS 2019
Featured articles
Letter from the Editor
Interview with Prof. Christian Bergmann
Treatable Traits in Chronic Inflammatory Airway Disease: Back to Basics
Treatable traits in chronic inflammatory airway disease: back to basics
Critical Care Medicine
Distinguishing between 4 different subtypes of sepsis sets the stage for individualised treatment
Stem cell therapy in acute respiratory distress syndrome improves 28-day mortality
SPICE III trial: Early sedation with dexmedetomidine in critically ill patients
SAATELLITE trial: Suvratoxumab prevents ventilator-associated Staphylococcus Aureus pneumonia in intensive care unit patients
Sleep Medicine
Million-patient study reveals gaps in long-term adherence among various sub-populations
Sleep apnoea severity has a non-linear relationship with acute myocardial infarction risk
Obstructive sleep apnoea affects morning spatial navigational memory processing in asymptomatic older individuals
Pulmonary Vascular Disease and Interstitial Lung Disease
Nintedanib reduces lung function decline in systemic sclerosis-associated ILD
Pulmonary arterial hypertension: early treatment with selexipag most effective
Long-term safety and efficacy of recombinant human pentraxin-2 in patients with idiopathic pulmonary fibrosis
Infection
Dupilumab improves outcomes in patients with severe chronic rhinosinusitis with nasal polyps and comorbid asthma
Durability of culture conversion in patients receiving ALIS for treatment-refractory MAC lung disease
E-cigarette use disrupts normal immune response to viral infections, particularly in women
Paediatric Pulmonary Medicine
Bacterial pneumonia predicts ongoing lung problems in infants hospitalised for acute respiratory failure
Aspergillus and early cystic fibrosis lung disease: does it need to be treated?
COPD
CORTICO-COP trial: eosinophil-guided therapy reduces systemic corticosteroid exposure
A randomised controlled trial of a smoking cessation smartphone application
Benralizumab does not ameliorate COPD exacerbations (GALATHEA/TERRANOVA trials)
Aclidinium bromide delays COPD exacerbation without increased MACE risk
Bench-to-Bedside (Pre-Clinical)
Human lung organoids to study foetal RSV infection
CRISPR/Cas9 genome editing therapy of hereditary pulmonary alveolar proteinosis
Cilia diagnostics in primary ciliary dyskinesia
Tuberous sclerosis complex 2 may be a novel target in pulmonary arterial hypertension therapy
Related Articles
February 18, 2021
Sotatercept: potential new treatment option for PAH
September 10, 2020
Intensive hypertension treatment lowers risk of orthostatic hypotension

November 30, 2021
The scope of remote healthcare in hypertension and hyperlipidaemia
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com